BAXTER INTERNATIONAL INC
BAXTER INTERNATIONAL INC (BAX) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
• Baxter is a slimmed-down hospital-products company partway through a restructuring: it sold its Kidney Care unit (Vantive) to Carlyle for $3.8 billion in early 2025 to pay down debt and installed a new operations-focused CEO in late 2025 [Source: Baxter 2025-2026 disclosures]. • The biggest near-term risk is leverage meeting weak guidance: net debt sits above $7 billion against a debt covenant that caps the net leverage ratio, while full-year 2026 adjusted EPS guidance of $1.85 to $2.05 came i
Is BAX overvalued? See what's priced in →
638 institutional managers reported holding BAX in 13F filings for the quarter ended 2026-03-31. 69 opened new positions that quarter. Held by BlackRock, Pzena Investment Management, Vanguard Group, among others. On the short side, 41.7M shares were sold short as of the 2026-06-15 count, about 8% of shares outstanding (6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BAX's share count grew 2.4% over the past five years even with $67.00M spent on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting); the current rate is $0.52 a share annually. Cash returned over the past three years: $1.24B in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at BAX over the trailing three years. Absence is a fact about the company, not a signal. 24 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BAX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-28 | -4.0% | -19.7% |
| 2023-11-03 | +3.6% | +15.3% |
| 2024-02-09 | +0.4% | +2.0% |
| 2024-05-03 | -8.6% | -5.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BAX's latest 8-K filings: 2026-07-14 (items 7.01, 9.01); 2026-05-08 (items 5.02, 5.03, 5.07, 9.01); 2026-04-30 (items 2.02, 8.01, 9.01); 2026-03-19 (items 7.01, 9.01); 2026-03-16 (items 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.